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Cystatin C is a strong inhibitor of cysteine proteinases expressed by diverse cells. Variant B cystatin C,
which was associated with increased risk of developing age-related macular degeneration, differs from
the wild type protein by a single amino acid (A25T) in the signal sequence responsible for its targeting
to the secretory pathway. The same variant conveys susceptibility to Alzheimer disease. Our investiga-
tions of the trafﬁcking and processing of variant B cystatin C in living RPE cells highlight impaired secre-
tion of extracellular modulators and inappropriate protein retention in RPE cells as potential molecular
mechanisms underpinning macular, and possibly neuronal, degeneration.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Cystatin C is a widely expressed, potent inhibitor of lysosomal
and extracellular cysteine proteinases. Its biochemical and struc-
tural characteristics, as well as its expression pattern in a large
number of human tissues and cells were extensively studied and
are presented brieﬂy in Sections 2 and 3, below, respectively.
In the retinal pigment epithelium (RPE), cystatin C was ﬁrstly
recognized as an abundant transcript by analysis of expressed se-
quence tags in cDNA libraries of human foetal and adult RPE cells
(Paraoan, Grierson, & Maden, 2000) – ﬁndings which were subse-
quently conﬁrmed in numerous studies both at transcriptional
and protein level (Buraczynska et al., 2002; Ida et al., 2004; Wasse-
lius, Hakansson, Johansson, Abrahamson, & Ehinger, 2001). Later
characterization of the intracellular processing of the protein iden-
tiﬁed the RPE as a major site for secretion of cystatin C in the pos-
terior eye (Paraoan, White, Spiller, Grierson, & Maden, 2001). More
recently, epidemiological association of a variant (known as vari-
ant B, described in Section 4 below) cystatin C with increased risk
of developing exudative age-related macular degeneration (AMD)
(Zurdel, Finckh, Menzer, Nitsch, & Richard, 2002) and subsequent
characterization of the unexpected trafﬁcking of the variant pro-
tein by RPE and other cells (Paraoan et al., 2004) drew attentionll rights reserved.
almology, School of Clinical
by Street, Liverpool L69 3GA,
(L. Paraoan).to essential molecular events previously not considered in the con-
text of the RPE-driven mechanisms of AMD pathogenesis.2. Structural and biochemical characteristics of cystatin C
Cystatin C, originally called gamma-trace and post-gamma-
globulin in early reports (Barrett, Davies, & Grubb, 1984; Brzin,
Popovic, Turk, Borchart, & Machleidt, 1984; Cejka & Fleischmann,
1973; Grubb & Lofberg, 1982; Turk et al., 1983), is the main amy-
loid-forming member of family 2 of the cystatin superfamily of
cysteine proteinase inhibitors that present two di-sulphide bridges
as deﬁning structural characteristics (for reviews see (Akopyan,
1991; Barrett, 1987; Paraoan & Grierson, 2007; Turk & Bode,
1991)). The active inhibitor is a single polypeptide chain consisting
of 120 amino acids residues (molecular weight of 13 kDa) and
exhibiting two distinct inhibitory sites conferring its dual inhibi-
tory speciﬁcity – as the tightest-binding inhibitor of cysteine pep-
tidases, such as cathepsins B, H, L and S (Abrahamson, Barrett,
Salvesen, & Grubb, 1986; Barrett et al., 1984; Turk & Bode, 1991),
as well as a strong competitive inhibitor of the lysosomal legumain
(Alvarez-Fernandez et al., 1999).
Functional studies have identiﬁed at least three regions as
important for the inhibitory activity of cystatin C: (i) the evolution-
ary conserved glycine residue in the N-terminal region (Gly-11) to-
gether with the three residues preceding it, which afford increased
afﬁnity for the target enzymes and optimal interaction with the
substrate-binding pockets of cysteine peptidases (Hall, Dalboge,
Grubb, & Abrahamson, 1993; Lindahl, Nycander, Ylinenjarvi, Pol,
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(Gln55-Gly59) involved in formation of a tight beta-hairpin loop
with essential role in binding cysteine proteinases (Bode et al.,
1988; Engh et al., 1993; Rodziewicz-Motowidlo et al., 2009); and
(iii) the Pro105-Trp106 region in the second hairpin loop with role
in anchoring the inhibitor to the proteinase once the complex has
been formed (Bjork et al., 1996). The high afﬁnity binding of cyst-
atin C to its target peptidases occurs through a competitive and
reversible two-step bimolecular mechanism (Barrett et al., 1984;
Nycander, Estrada, Mort, Abrahamson, & Bjork, 1998).
The propensity of cystatin C to form inactive dimers and oligo-
mers involved in subsequent formation of amyloid protoﬁlaments/
deposits is attributable to a process of three-dimensional domain
swapping (Ekiel & Abrahamson, 1996; Janowski et al., 2001; Stani-
forth et al., 2001). This process occurs in vitro under pre-denaturing
conditions while in vivo it is signiﬁcantly enhanced in the presence
of an N-truncated form, which is the main form of cystatin C found
in amyloid deposits (Janowski, Abrahamson, Grubb, & Jaskolski,
2004). The oligomerization is dramatically accelerated in the case
of a naturally occurring, rare (Icelandic) L68Q mutant variant –
the causative factor for an autosomal dominant form of hereditary
cystatin C amyloid angiopathy – which retains the inhibitory activ-
ity but has decreased stability yielding dimers at physiological
temperatures and generates cystatin C amyloid deposits in cerebral
blood vessels that lead to fatal amyloidosis in early adult life (Abra-
hamson, 1996; Cohen, Feiner, Jensson, & Frangione, 1983; Ghiso,
Jensson, & Frangione, 1986). Notably, both L68Q mutant variant
and the N-truncated form of cystatin C are structurally different
from the AMD- and Alzheimer (AD)-associated variant, called var-
iant B cystatin C, whose characteristics are presented in detail in
Section 4 below.
3. Overview of expression and localization of cystatin C
Presence of cystatin C has been investigated and demonstrated
in a variety of tissues, including salivary glands, brain, testis, sem-
inal vesicles, liver, pancreas, lung, placenta and various endocrine
glands (Abrahamson et al., 1990; Grubb & Lofberg, 1982; Lofberg,
Nilsson, Stromblad, Lasson, & Olsson, 1982; Lofberg et al., 1983).
Outside the eye, the highest transcriptional levels of cystatin C,
indicated by a semi-quantitative comparative analysis in a wide
variety of adult and foetal tissues, appear in salivary glands andFig. 1. Northerm blot analysis of cystatin C expression. (A) Messenger RNA samples from
View, USA) were hybridized to a 32P-labelled cystatin C probe derived from a full length cy
indicated in the diagram alongside the blot. All brain-derived tissues represented in the b
with the exception of the spleen, present a moderate level of expression compared w
transcripts in each tissue that hybridize to the probe. (B) Hybridization of mRNA from hum
C-speciﬁc probe identiﬁes two closely related transcripts of approximately 850–900 nucl
size markers on lane 2.neuronal tissues (Fig. 1A). Although the speciﬁc cells responsible
for cystatin C synthesis have not been elucidated for all tissues in
which the presence of the inhibitor has been documented, some
likely contributors are brain cortical neurons and astrocytes (Lof-
berg, Grubb, & Brun, 1981; Yasuhara et al., 1993), pancreatic islet
A cells (Lignelid & Jacobsson, 1992) and various (neuro)endocrine
cells including chromafﬁn cells of the adrenal medulla (Lofberg
et al., 1982) and thyroid calcitonin producing cells (Lofberg et al.,
1983).
Remarkably, cystatin C is present in most biological ﬂuids,
including urine, blood serum and cerebrospinal ﬂuid, in concentra-
tions implying a physiological role (Abrahamson et al., 1986; Lof-
berg & Grubb, 1979; Sickmann et al., 2000). As such, it is thought
to be a major local regulator of extracellular proteolytic activity.
In the cerebrospinal ﬂuid (CSF) cystatin C is the dominating cys-
teine proteinase inhibitor (with a 5.5 ratio concentration over that
in blood plasma (Lofberg & Grubb, 1979)). Notably, the brain tissue
with the highest cystatin C mRNA level is the choroid plexus (Cole
et al., 1989), thus explaining the supply of cystatin C to the CSF
which is produced mainly by the choroid plexus.
In the eye, prior to the identiﬁcation of the RPE as a major site of
cystatin C expression (Paraoan et al., 2000), two partially contra-
dictory studies represented the sum total of the literature on cyst-
atin C expression. Both studies examined the presence of cystatin C
mRNA and concluded that in the rat eye the inhibitor is expressed
only in the sclera and retina (with a tentative association of the ret-
inal signal with glia and rods) (Barka & van der Noen, 1994), while
in the chick eye the expression is localized to the epithelium of the
ciliary body and nowhere else (Colella, 1996). The differences were
put down to species variation and to a possible shift in the site of
expression during evolution of mammalian species. The ﬁnding of
high incidence of cystatin C precursor expressed sequence tags in
cDNA libraries of RPE cells (Paraoan et al., 2000) is further substan-
tiated by the detection of two related transcripts of about 850–900
nucleotides in RPE cells (Fig. 1B). Notably, the presence of two cyst-
atin C mRNAs was previously observed also in non-ocular tissues,
pointing towards some tissue speciﬁcity of closely related alterna-
tive splice variants (Cole et al., 1989; Tsuruta, O’Brien, & Griswold,
1993). However, the mRNA variants detected in RPE cells corre-
spond to alternative splice variants known to differ only in the
untranslated regions and to encode same length (146 amino acids)
precursor proteins (see CST 3 under AceView genesvarious tissues in the Human RNAMaster Blot (Clontech Laboratories, Inc., Mountain
statin C cDNA clone isolated in-house (Paraoan et al., 2000). Tissues represented are
lot, as well as the spinal cord show a considerable level of expression. Foetal tissues,
ith adult tissues. Hybridization signals represent the pooled signal of all related
an RPE cells, subjected to formaldehyde agarose gel electrophoresis, to the cystatin
eotides (lane 1); ribosomal subunits from yeast total RNA were separated to serve as
Fig. 2. Immunohistochemical analysis of cystatin C in human eyes. Sections were exposed to a polyclonal rabbit anti-Cystatin C antibody (Upstate/Millipore).
Immunoreactive sites were revealed with red chromogen AEC (Dako Envision); haematoxylin counterstain. Strongest immunoreactivity is detected in the RPE cell layer (A).
Cystatin C is also seen in the multistratiﬁed epithelium of the ciliary body – CBE (C), lens epithelium – LE (D), cells in the ganglion cell layer of the retina (arrow) (E) and in the
vitreous (F). Panel B shows a negative control in which the primary antibody was substituted with normal serum. Scale bars represent 50 lm. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Immunohistochemical analysis of whole human eyes sections
(Fig. 2) reveals immunoreactivity for cystatin C protein in the neu-
rorepithelium of the iris, ciliary body, lens epithelium and RPE,
with the strongest and most conﬂuent staining present in the
RPE. Inﬂammatory cells in the uveal tract and some cells in theneuroretina, mostly in the ganglion cell layer, are positive. The cor-
nea, trabecular meshwork, iris stroma, uveal stroma, optic nerve
and sclera are negative. The vitreous (especially base) also contains
cystatin C (Fig. 2F). Staining of the ciliary body epithelium (Fig. 2C)
is consistent with reports of cystatin C in the aqueous (Russell &
Epstein, 1992; Wasselius, Hakansson, Abrahamson, & Ehinger,
2004). Similar distribution of cystatin C was reported in mouse
740 L. Paraoan et al. / Vision Research 50 (2010) 737–742and rat eye, with the main difference being the presence of cystatin
C in the cornea and iris stromal cells in rodents (Wasselius et al.,
2001, 2004).
4. Variant B cystatin C
The human precursor cystatin C gene, CST 3, (accession number
NM_000099) is located alongside the majority of type 2 cystatin
genes and pseudogenes in the cystatin locus on chromosome 20
(gene map locus 20p11.21; (Abrahamson, Islam, Szpirer, Szpirer,
& Levan, 1989; Schnittger, Rao, Abrahamson, & Hansmann,
1993)). The gene encodes a 146 amino acids precursor whose
highly hydrophobic N-terminal sequence of 26 amino acids
residues was demonstrated experimentally to function as a signal
sequence directing the precursor to the secretory pathway
in RPE and other cells (Paraoan, Grierson, & Maden, 2003; Paraoan
et al., 2001). A variation in the CST 3 gene was recently
designated ARMD11 (http://www.ncbi.nlm.nih.gov/entrez/dispo-
mim.cgi?id=611953) and is characterized by three KspI (SstII) poly-
morphisms at positions 157 and 72 in the 50 untranslated
region and at position +73 of the coding sequence of the transcript
(Balbin & Abrahamson, 1991). However, as a result of strong link-
age disequilibrium, all three polymorphisms appear linked and de-
ﬁne a single variant allele named variant B (with a frequency in
population of 0.29) in addition to the wild type one, also referred
to as variant A (whose frequency is 0.71) (Balbin & Abrahamson,
1991; Finckh et al., 2000).
One of the polymorphisms mentioned above translates into an
amino acid substitution in the penultimate position of the signal
sequence of precursor cystatin C, namely A25T in the variant B.
The substitution does not affect any of the protein’s domains in-
volved in its biochemical/inhibitory function. However, the A25T
substitution has striking consequences on the trafﬁcking and intra-
cellular processing of the variant precursor (Paraoan et al., 2004).
Thus, processing of the variant B cystatin C through the secretory
pathway in RPE cells is signiﬁcantly impaired through a mecha-
nism dependent on the reduced hydrophobicity of the signal se-
quence which is affected by the substitution (Ratnayaka et al.,
2007) and results in a reduction by approximately half of the se-
creted, mature cystatin C (Paraoan et al., 2004). Furthermore, the
unprocessed or partially processed variant B precursor cystatin C
associates surprisingly with the mitochondria (Fig. 3A) in a mannerFig. 3. Intracellular localization and trafﬁcking of variant B (A25T) precursor cystatin C (
Confocal micrographs of living human RPE cells transiently transfected with (A) variant B
C-EGFP and (C) EGFP only, 24 h post-transfection. Green ﬂuorescence image is merged
(Molecular Probes™, Invitrogen, Paisley, UK) concentrated in the mitochondria of activel
with mitochondria (indicated by yellow colour); some diffuse green ﬂuorescence is also
cystatin C is to the ER/golgi apparatus (B), as previously described (Paraoan et al., 2001).
(C) to illustrate cell morphology. (For interpretation of the references to colour in this ﬁnot dependent on the mitochondrial membrane potential and sug-
gestive of a relative anchorage in the mitochondrial membrane
system (Paraoan et al., 2004). A small but distinct amount of vari-
ant B molecules also appear diffusely throughout the cytoplasm
and nucleus, but not nucleoli in RPE cells. The implications for
the biology of RPE cells of both reduced secretion and intracellular
mislocalization of the variant B cystatin C were discussed at large
previously (Paraoan et al., 2004). Reduced secretion of cystatin C
is likely to affect the proteolytic balance in the extracellular space
of the RPE cells with possible consequences on attachment of cells,
extracellular transport mechanisms and/or neovascularization.
Conversely, the inappropriate association of the variant inhibitor
with the mitochondria, alongside a gradual increase of intracellular
misfolded protein may lead to further, progressive functional
impairment of the RPE.
5. Involvement in disease of the variant B cystatin C
Homozygosity for variant B cystatin C allele was shown to cor-
relate with increased risk of developing exudative AMD and with a
relative early onset of the disease (Zurdel et al., 2002). The data
pointed to the CST 3 haplotype B acting as a recessive allele con-
tributing to AMD risk in up to 6.6% of the patients investigated in
the above study, with an odds ratio for disease association with
the CST 3 B/B genotype of 2.97 (95% conﬁdence interval [CI]:
1.28–6.86). There are no studies to date investigating the effect
of CST 3 haplotype B in the presence of other contributory factors
to the multifactorial etiology of exudative AMD.
A series of studies over the last decade addressed the associa-
tion of cystatin C and neurological disorders, with particular
emphasis on neuronal degenerative pathology. These studies were
in part triggered by the detection of cystatin C co-deposited with
b-amyloid protein in amyloid deposits, in senile plaques and in
arteriolar walls in the brain of AD patients (Levy et al., 2001), sug-
gesting involvement of the protein in the pathogenic processes
leading to amyloid deposition. A signiﬁcant genetic association
was unveiled between CST 3 B/B genotype and late-onset AD with
an overall 3.8 odds ratio (95% CI: 1.56–9.25) for AD in association
with the respective genotype (Finckh et al., 2000) and a doubled
risk to develop the disease for homozygous patients over 80 years
old (Crawford et al., 2000). Although CST 3 appears to act indepen-
dently of the apolipoprotein E gene (APOE), the ﬁnding thatA) is dramatically altered compared with that of wild-type precursor cystatin C (B).
cystatin C fused to enhanced green ﬂuorescent protein (EGFP), (B) wild-type cystatin
in (A) with the red ﬂuorescence of the oxidated Mitotracker Red CM-H2Xros dye
y respiring cells. The majority of variant B precursor cystatin C molecules colocalize
present in the cytoplasm and nucleus. In contrast, targeting of wild-type precursor
Bright ﬁeld image is overlaid with the image of RPE cells transfected with EGFP only
gure legend, the reader is referred to the web version of this article.)
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disease (Finckh et al., 2000) raises the possibility that the combina-
tion of adverse alleles of CST 3 and APOE leads to an accelerated
upsetting of the intracellular processing of cellular fractions in-
volved in AD pathology. This hypothesis is further supported by
the ﬁnding of a synergistic association between the variant B CST
3 haplotype, APOE4 and AD in patients between 60 and 74 years
old (Beyer et al., 2001; Cathcart, Huang, Lanham, Corder, & Poduslo,
2005).
While variant B cystatin C allele has become ﬁrmly recognized
as a potential AD susceptibility gene (Bertram, McQueen, Mullin,
Blacker, & Tanzi, 2007) and the protective role of the wild type
cystatin C in AD pathogenesis has been established (Kaeser et al.,
2007; Mi et al., 2007), the functional effects of the variant protein
in neurons remain to be clariﬁed. Conversely, in relation to the eye
pathology there is an obvious need for study of possible interac-
tions of the CST 3 haplotype B with other known genetic determi-
nants, including APOE4, of the AMD.
Our investigation into the processing and trafﬁcking of variant B
cystatin C in living RPE cells has highlighted two molecular mech-
anisms previously not considered in relation to AMD, and possibly
AD, pathology: (i) reduced secretion of modulators of extracellular
environment; and (ii) inappropriate intracellular retention and tar-
geting of proteins, other than in drusen or amyloid format. The spe-
ciﬁc consequences upon RPE cells of the reduction of extracellular
function of cystatin C and of its intracellular accumulation around
mitochondria are currently addressed in our laboratory. It is likely
that at least some of the functional effects of, on one hand, the im-
paired secretion of a major regulator of proteolysis and, on the
other, of the errant intracellular accumulation of the variant pro-
tein are shared by RPE and neuronal cells on the progressive path
to respective pathologies.
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